Genprex, INC Form 4 insider transactions

Director Brent Longnecker sold a total of 18 shares of Genprex, Inc. common stock for tax purposes.

Genprex's Chief Medical Officer, Mark Stanley Berger, reported a disposition of 7,168 common shares for tax obligations related to RSU vesting.

Genprex, Inc. President, CEO, and CFO Ryan M. Confer disposed of 9,330 shares of common stock on February 27, 2026, to cover tax withholdings from RSU vesting.

Genprex, Inc. Director Jose Antonio Moreno Toscano received 9,000 Restricted Stock Units, with vesting contingent on service, following a 1-for-50 reverse stock split.

Genprex's Chief Medical Officer, Mark Stanley Berger, was granted 28,500 Restricted Stock Units, vesting over two years.

Genprex, Inc. CEO Ryan Confer received an award of 45,000 Restricted Stock Units under the company's equity incentive plan, vesting over two years.

Genprex, Inc. Director Brent M. Longnecker acquired 9,000 Restricted Stock Units under the company's equity incentive plan following a 1-for-50 reverse stock split.

Genprex, Inc. Director William R. Wilson Jr. was granted 9,000 Restricted Stock Units, vesting by August 2026.

Genprex's Chief Medical Officer, Mark Stanley Berger, disposed of 4,500 common shares to satisfy tax withholding obligations related to the vesting of Restricted Stock Units.

Genprex, Inc. President, CEO, and CFO Ryan M. Confer reported a disposition of 5,775 shares of common stock on June 30, 2025, to satisfy tax withholding obligations related to the vesting of Restricted Stock Units.

Chief Medical Officer Mark Berger disposed of 585 shares of Genprex stock on February 18, 2025, to cover tax obligations related to vesting Restricted Stock Units.

Ryan Confer, President, CEO, and CFO of Genprex, Inc., reports the withholding of shares to cover tax obligations related to vested Restricted Stock Units.

Genprex director Jose Antonio Moreno Toscano acquired 4,750 restricted stock units, which will vest on June 30, 2025, or the day before the next annual meeting.

Genprex director William R. Wilson Jr. acquired 4,750 restricted stock units (RSUs) and now holds 7,845 shares following a recent transaction.

Genprex director Brent Longnecker acquired 4,750 restricted stock units and disposed of 500 shares of common stock.

Genprex CEO Ryan Confer was granted 29,375 restricted stock units (RSUs) that vest on June 30, 2025.

Genprex's Chief Medical Officer, Mark Stanley Berger, was granted 18,250 restricted stock units (RSUs) that will vest on June 30, 2025.